CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathwaysXuejiao Liu, Rutong Yu|Journal of Hematology & Oncology|2016Cited by 80
MELK Inhibition Effectively Suppresses Growth of Glioblastoma and Cancer Stem-Like Cells by Blocking AKT and FOXM1 PathwaysXu Zhang, Xuejiao Liu|Frontiers in Oncology|2021Cited by 46
RETRACTED ARTICLE: GRP78 determines glioblastoma sensitivity to UBA1 inhibition-induced UPR signaling and cell deathGuanzheng Liu, Xuejiao Liu|Cell Death and Disease|2021Cited by 42
MALT1 is a potential therapeutic target in glioblastoma and plays a crucial role in EGFR‐induced NF‐κB activationXuejiao Liu, Rutong Yu|Journal of Cellular and Molecular Medicine|2020Cited by 32
FoxR2 promotes glioma proliferation by suppression of the p27 pathwayXuejiao Liu, Rutong Yu|Oncotarget|2017Cited by 12